Enhanced tax sops for R&D on pharma budget wish list

UPSC Prelims + Mains Study Note

1. At a Glance

• India's pharmaceutical sector is demanding enhanced tax incentives for R&D, including restoration of weighted deductions under Section 35(2AB) of the Income Tax Act, faster depreciation on compliance investments, and easier export credit access — ahead of Union Budgets 2025–26/2026–27. [1]
• The ask is rooted in structural weaknesses: India spends only ~2% of pharma revenue on R&D versus global majors spending 15–20%, making fiscal nudges critical to shift from a generic-cost model to an innovation-led model. [4]
• Linked to India's broader Atmanirbhar Bharat in Pharma goal: reducing import dependence on Active Pharmaceutical Ingredients (APIs), especially from China, and scaling export competitiveness. [2]
• UPSC relevance: GS-III (Indian Economy — industrial policy, science & technology), Budget analysis, and Science & Technology (pharmaceutical innovation). [4]

2. Why in the News

• January 15, 2026: Industry body Pharmexcil (Pharmaceuticals Export Promotion Council of India), through Vice Chairperson Bhavin Mehta (Whole Time Director, Kilitch Drugs), placed on public record pharma sector's pre-Budget demands including: enhanced R&D tax incentives, faster depreciation for quality/compliance investments, easier export credit, and rationalisation of import tariffs on critical raw materials. [1]
• Context: Union Budget 2026–27 is imminent; industry lobbying period typically runs November–January. [1]
• Pharmexcil also called for policy continuity on PLI and PRIP schemes, while demanding the "next phase" focus on scale, execution, and global cost competitiveness. [1]
• Parallel trigger: Weighted deduction under Section 35(2AB) was reduced from 200% → 150% → 100% over successive budgets, seen as a rollback that disincentivised corporate R&D. [5]

3. Background & Evolution

4. Core Static Facts

Tax Framework

• Section 35, Income Tax Act, 1961: Deductions for scientific research expenditure
• Section 35(2AB): In-house R&D deduction for companies in biotechnology, pharma, manufacturing — facility must be DSIR-approved (Department of Scientific & Industrial Research)
• Current rate: 100% (plain deduction; no weighted uplift). Industry demands 150–200% restoration [5]
• Section 115BAB: Concessional corporate tax (15%) for new manufacturing companies — industry seeks alignment with enhanced R&D deduction [5]

Key Schemes

• Implementing Ministry: Ministry of Chemicals and Fertilizers (Dept. of Pharmaceuticals) [2]
• Regulatory/DSIR approval: Mandatory for claiming Section 35(2AB) deductions
• Pharmexcil = Pharmaceuticals Export Promotion Council of India (under MoC&F)
• PLI covers 55 selected applicants; incentive period FY2023–FY2028 [3]
• PRIP targets ~300 projects catalysing ₹11,000 crore total R&D investment [2]

5. Multi-Dimensional Analysis

Economic

• India is the 3rd largest pharma producer by volume and 14th by value globally — the gap signals underinvestment in innovation.
• R&D tax sops directly reduce the effective cost of innovation; restoration to 200% deduction would lower effective tax outgo for R&D-intensive firms.
• APIs: ~65–70% of India's API requirements historically imported from China; domestic API push critical for supply-chain resilience. [2]
• PLI investment overperformance (₹37,306 crore vs. ₹17,275 crore target) signals high private-sector appetite if fiscal conditions are right. [3]

Scientific / Technological

• India's pharma R&D gap: largely focused on reverse engineering generics rather than new chemical entity (NCE) discovery.
• PRIP scheme specifically targets biosimilars, complex generics, and novel medical devices — areas requiring sustained 5–10 year R&D cycles. [2]
• Faster depreciation on quality/compliance equipment (WHO-GMP, US FDA standards) would reduce the cost of export-oriented upgrades.
• Weighted deductions historically incentivised DSIR-registered in-house R&D labs — their rollback slowed lab registrations.

Geopolitical / Strategic

• API import dependence on China (~65–70%) is a strategic vulnerability exposed acutely during COVID-19 pandemic disruptions.
• Pharmexcil's budget demand for export credit easing targets higher pharma exports — India already exports to ~200 countries; target to double from ~$25 billion. [1]
• Rationalisation of import tariffs on critical raw materials (intermediates, KSMs) linked to making Indian APIs globally cost-competitive against Chinese producers.

Legal / Constitutional

• Entry 52, List I (Union List): Industries declared by Parliament to be in national interest — pharmaceuticals regulated centrally.
• Tax incentives legislated via annual Finance Bills amending the Income Tax Act, 1961.
• DSIR approval for R&D labs governed by DSIR Rules, 1986.

Administrative

• Bottleneck: DSIR registration process is lengthy; delays effectively defer the tax benefit to companies.
• PLI scheme execution monitored by Dept. of Pharmaceuticals under Ministry of Chemicals & Fertilizers.
• Coordination gap between DST/DSIR (R&D approval), DoP (PLI/PRIP), and Finance Ministry (tax policy) creates policy silos. [2]

Ethical / Governance

• Risk of rent-seeking: weighted deductions historically misused by routing non-R&D capital as "R&D expenditure."
• Need for outcome-linked R&D incentives (patents filed, clinical trials completed) rather than pure expenditure-based deductions.

6. Recent Developments (last 12–18 months)

• Jan 2025: Pharmexcil pre-Budget 2025–26 submission called for PLI extension and export credit improvements. [1]
• Feb 2025: Union Budget 2025–26 — no major restoration of weighted R&D deductions; industry expressed disappointment.
• Mid-2025: PRIP scheme issued call for proposals worth ~₹11,000 crore; around 300 projects targeted in drug discovery, biosimilars, medical devices. [2]
• Aug 2025: PLI for pharma cumulative investment reported at ₹37,306 crore — more than double the original committed target. [3]
• Jan 15, 2026: Pharmexcil formally places pre-Budget 2026–27 demand for enhanced R&D tax sops, faster depreciation, and eased export credit on public record. [1]
• Ongoing (2025–26): Government review of National Pharma Policy and potential rationalisation of import tariffs on API raw materials. [4]

7. Prelims Hooks

1. Section 35(2AB) of Income Tax Act, 1961 governs weighted deduction for in-house R&D by manufacturing companies — approval required from DSIR (not DBT). [5]
2. The weighted R&D deduction under Section 35(2AB) was progressively reduced from 200% → 150% → 100% — currently at 100% (no weighted uplift). [5]
3. PLI Scheme for Pharmaceuticals approved by Union Cabinet on 24 February 2021 with outlay of ₹15,000 crore for 6 years. [3]
4. PLI pharma covers 55 selected applicants incentivised for production of biopharmaceuticals, complex generics, anti-cancer drugs, and patented drugs. [3]
5. PRIP Scheme (Promotion of Research & Innovation in Pharma-MedTech Sector) has an approved outlay of ₹5,000 crore; targets ~300 projects with total R&D investment of ₹11,000 crore. [2]
6. Implementing ministry for both PLI-Pharma and PRIP: Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals). [2]
7. Pharmexcil = Pharmaceuticals Export Promotion Council of India — the nodal body for pharma export promotion under the Ministry of Commerce/DoP. [1]
8. India is the 3rd largest pharmaceutical producer by volume globally but 14th by value — reflecting the generic-heavy, low-innovation profile.
9. India's API import dependence on China estimated at ~65–70% — the core rationale for Bulk Drug Parks and API-PLI schemes. [4]
10. DSIR (Department of Scientific and Industrial Research) — under Ministry of Science & Technology — is the mandatory approving authority for in-house R&D labs claiming Section 35 deductions. [5]
11. Bulk Drug Parks scheme: ₹3,000 crore outlay for API cluster manufacturing — distinct from PLI-Pharma.
12. PLI pharma cumulative investment as of March 2025: ₹37,306 crore against committed target of ₹17,275 crore. [3]

8. Mains Relevance

GS Paper Mapping

Plausible Mains Question Stems

1. "India's pharmaceutical sector is a global leader in generic drug supply but lags in innovation. Critically examine the efficacy of tax incentives and PLI schemes in bridging this gap." (GS-III)
2. "Examine how restoration of weighted tax deductions under Section 35(2AB) of the Income Tax Act can complement the PRIP scheme in transforming India into a pharma innovation hub." (GS-III)
3. "Discuss India's strategic vulnerabilities arising from API import dependence and evaluate the policy measures taken to achieve self-reliance in Active Pharmaceutical Ingredients." (GS-III / GS-II)

9. Related Topics to Study Next

1. PLI Scheme (overall architecture) — Parent policy under which pharma PLI operates; 14 key sectors, ₹1.97 lakh crore total outlay.
2. Section 35 & R&D Tax Policy in India — Broader Income Tax Act provisions; compare with global practices (US R&D tax credit, UK Patent Box).
3. National Pharmaceutical Policy / Draft Pharma Policy — Overarching regulatory and pricing framework governing the sector.
4. API & Bulk Drug Parks Scheme — Direct complement to PLI; addresses the import-substitution angle on raw materials.
5. Atmanirbhar Bharat in Pharma — Links pharma self-reliance to national security; connects to COVID-19 supply-chain lessons.
6. DSIR & Technology Development Board — Institutional machinery for R&D promotion; needed to understand administrative bottlenecks.
7. Biosimilars & Patent Cliff — Scientific context behind PRIP; why India's pharma window of opportunity exists in the 2025–30 period.
8. TRIPS Agreement & Compulsory Licensing — WTO-TRIPS interface with pharma innovation and generic access; connects Section 3(d) of Patents Act.

10. Common Errors / Trap Areas

1. Wrong ministry: DSIR (approving authority for R&D labs) is under Ministry of Science & Technology — not Ministry of Chemicals & Fertilizers. PLI-Pharma/PRIP are under Chemicals & Fertilizers. Confusing the two is a classic trap.
2. Weighted deduction percentage: Aspirants often cite 200% as the current rate — it has been reduced to 100% (the plain deduction level). The demand is for restoration to higher rates.
3. PRIP vs. PLI: PRIP (₹5,000 cr) ≠ PLI-Pharma (₹15,000 cr). PRIP is innovation/R&D-specific; PLI is manufacturing/production-output-linked. Do not conflate.
4. Pharmexcil vs. FICCI/CII: Pharmexcil is the export-specific industry body under DoP; general industry demands come from FICCI/CII. Attribution errors appear in data interpretation questions.
5. Section 35 vs. Section 80IC/80IB: Section 35 covers R&D expenditure deductions; Sections 80IC/80IB cover location-based manufacturing incentives (special category states, SEZs). These are frequently mixed up in tax-law MCQs.